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ABSTRACT: Isosorbide was functionalized with furoxan for the first 
time to give adducts that release nitric oxide up to 7.5 times faster 
than the commercial vasodilator, isosorbide-5-mononitrate (Is5N). 
The synthesis was facilitated by MeMgCl-mediated selective 
acetylation of isosorbide or selective deacetylation of isosorbide-2,5-
diacetate, which was rationalised in terms of a more stable 5-
alkoxide magnesium salt using DFT. Isosorbide-furoxans are safer 
to handle than Is5N due to greater thermal stability.  
Nitric oxide (NO) is a reactive free radical with a vast array of 
physiological functions,1 in cancer,2 anti-microbial 
processes,3 wound healing,4 and most significantly, 
vasodilation.5 Clinically, nitrate ester drugs are used to effect 
vasodilation. Nitroglycerin, pentaerythritol tetranitrate, 
isosorbide dinitrate (IsDiN), and isosorbide-5-mononitrate 
(Is5N, Scheme 1A) are prescribed to patients suffering from 
angina, where released NO induces relaxation of vascular 
smooth muscles (vasodilation) to reduce blood pressure.6 
Nitrate esters however, are well-known explosives,7 including 
IsDiN, a particularly hazardous side-product in the 
manufacture of Is5N.8 Furoxans (1,2,5-oxadiazole 2-oxides) 
are highly energetic molecules,9 heralded as alternative NO-
donors.10-15 The Cassella-Hoechst drug, CAS 1609, is a furoxan 
with potent and long-lasting vasodilation,10,11 and is devoid of 
the tolerance associated with nitrate ester drugs.16 Isosorbide 
(1) is a sustainable feed-stock industrially produced from the 
double dehydration of D-sorbitol.17 Apart from the nitrate 
esters, there are few valuable derivatives of 1 due to 
difficulties in selective functionalization and substitution at 
the 2- and 5-hydroxyl groups.18 Herein, for the first time, 
furoxan is combined with isosorbide (1), and in doing so, we 
have developed a simple and selective acetylation protection-
deprotection protocol for scaffold 1 (Scheme 1B).  
Scheme 1. (A) Is5N and furoxan drugs (B) Protection-
deprotection of isosorbide 1 allowing selective func-
tionalization with furoxan 
 
  
 The two hydroxyls of 1 are non-equivalent with an exo 2-
OH and endo 5-OH having different reactivities. The more 
nucleophilic nature of the 5-OH is attributed to activation 
via H-bonding with the oxygen of the adjacent cycle.19 
Despite the difference in reactivity, base-mediated 
acetylations and alkylations are unreliable and low yielding, 
with the only reported selective acetylation of 1 using 
harmful PbO in Ac2O to give isosorbide-5-acetate (2a).20 
Acetylation with Ac2O alone gives mixtures of isosorbide 
acetates with 5-acetate 2a the major product, but in low 
recovered yields.21 The literature reported syntheses of 
isosorbide-2-acetate (2b) are inadequately selective with 
significant draw-backs. Preparations of 2b have used DCC-
mediated coupling with poor atom-economy,22 and reduced-
pressure distillation from mixtures of isosorbide-acetates.20 
More specialized enzyme-mediated acetylation of 1, and 
enzyme-mediated hydrolysis of isosorbide-2,5-diacetate 5 
have been reported.23 Inexpensive MeMgCl has found 
application as a non-nucleophilic base, including in the 
Roche AG industrial deprotonation of secondary amines and 
α-deprotonation of nitriles.24 Herein, the selective 
acetylation of the 2-OH and 5-OH of 1 was achieved by 
simply altering the number of equivalents of MeMgCl, as part 
of a protection-deprotection strategy that allowed facile 
alkylation to give unique furoxan NO-donors in high yields. 
 NaH and BuLi in combination with Ac2O gave low 
conversions with little selectivity toward the 2- or 5-positions 
of isosorbide 1 (Table 1). MeMgCl (1.1 equiv) and Ac2O 
provided high conversion and selectivity for acetylation at 
the 5-position, with 5-acetate 2a isolated in 73% yield. By 
simply increasing the amount of MeMgCl (>2 equiv), a 
switch in selectivity of acetylation was achieved with the 
isomeric 2-acetate 2b as the major product, occurring in a 
ratio of 45 : 1 over 2a. Conversion was low, however, and 
replacing Ac2O with more reactive AcCl enabled near 
complete conversion of 1 to 2b in 78% isolated yield, with 
trace levels (<0.5%) of isomer 2a detected by GC (Figure S2).  
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base (equiv) 1 (%)a 2a (%)b 2b (%)b 5 (%)b 
NaH (1.1) 47 30 8 15 
BuLi (1.1) 24 40 12 25 
MeMgCl (1.1) 10 76 (73)c 2 13 
MeMgCl (2.8) 43 1 45 11 
MeMgCl (2.8)d 6 - 82 (78)c 12 
MeMgCl (1.3)e 3 - 88 (83)c 9 
See Table S1 for full list of optimization experiments. a Con-
version determined by gravimetry. b Conversion determined 
by GC. c Isolated yield. d 0 °C, AcCl (1 equiv) as acetylation 
agent. e Ac2O (2.5 equiv), Amberlite® IR-120, 2 h, 80 °C, then 
filtration, evaporation and addition of MeMgCl, THF, reflux, 
8 h. 
 
DFT modelling was used to investigate this remarkable 
selectivity of deprotonation by assessing the stability of 
+MgCl complex 6a relative to 6c (Scheme 2) formed through 
ethereal (THF-like)25 chelation to the adjacent ring oxygen 
atom in the isosorbide substrate. DFT was carried out in the 
gas phase, since solvent effects (the role of THF) would not 
affect the relative energies of the observed isosorbide 
complexes. Two conformations of 1 were of interest; the 
minimum energy model and an alternative conformer 
1.0 kcal/mol higher in energy. Starting from the minimum 
energy conformer 1, coordination of the +MgCl ion was 
preferred at the 5-alkoxide 6a by 11.7 kcal/mol over the 
strained 2-alkoxide 6c. The greater stability of 6a arises from 
more effective +MgCl coordination to the oxygen atom on the 
adjacent ring with steric hindrance from the isosorbide 
junction 3,4-hydrogens affecting coordination in complex 6c. 
The energy minimum conformation of 1 preferentially gave 
2-alkoxide complex 6b, with ethereal +MgCl coordination 
within the same ring, over 2-alkoxide 6c by 2.7 kcal/mol. 
Moreover, +MgCl coordination to 2-alkoxide 6c was only 
possible using the higher energy alternative conformer of 1. 
The enhanced stability of 5-alkoxide 6a over 2-alkoxide 
complexes 6b and 6c was reflected in shorter Mg+···-OR 
(alkoxide) and Mg+···OR2(ether) bond distances (Table S3).  
   
 
Scheme 2. DFT of proposed alkoxide intermediates 
from the reaction of isosorbide 1 with MeMgCl a 
 
a All geometry optimizations were performed using Gauss-
ian 16W/GaussView 6 with DFT B3LYP functional in the gas 
phase and a 6311G (2d,p) basis set.26 Mg and Cl atoms depict-
ed in blue and green, respectively. Table S2 contains model 
energies in Hartrees. 
 
Upon addition of >2 equiv of MeMgCl, both the 2- and 5- 
OHs of 1 were deprotonated, and acetylation occurred at the 
less stable, more reactive 2-alkoxide, delivering a switch in 
selectivity to give 2b. DFT modelling supported the 
greater stabilization of +MgCl at the 5-alkoxide in the 2,5-
dialkoxide complex with shorter bond lengths between 
Mg+···-OR(alkoxide) and Mg+···OR2(ether) compared with 
+MgCl coordination at the 2-position (Figure S3). Using the 
principle of forming the more thermodynamically stable 
+MgCl intermediate (i.e. the 5-alkoxide, analogous to 6a), a 
selective mono-deacetylation of isosorbide-2,5-diacetate 5 
 with MeMgCl (1.3 equiv) was carried out (Table 1). The multi-
gram synthesis of isosorbide-2-acetate (2b) was achieved in 
83% yield without the requirement for chromatography with 
diacetate 5 formed in situ from 1 using Ac2O and Amberlite® 
IR-120 catalyst. 
With the 2- or 5-positions on isosorbide effectively 
blocked through acetylation, functionalization of the 
available hydroxyl with furoxan was now possible. Furoxan 
electrophiles 7a and 7b can be readily prepared in two steps 
from their respective cinnamyl alcohols (see Supporting 
Information).14,15 Alkylation with the furoxan bromides 7a 
and 7b was mediated by Ag2O. Reaction of 5-acetate 2a with 
bromide 7a yielded isosorbide-5-acetate-2-furoxan 3a in 81% 
yield with furoxan attachment at the exo-position confirmed 
by X-ray crystallography (Scheme 3).  
 
Scheme 3. Synthesis of isosorbide-2-furoxan 4a and 
X-ray crystal structure of 3a (thermal ellipsoids set at 
40% probability) 
 
 
Deprotection of 5-acetate 3a through basic hydrolysis 
afforded isosorbide-2-furoxan 4a in 91% yield. Similarly, 
synthesis of furoxan isomer 4b from 2-acetate 2b via 
isosorbide-2-acetate-5-furoxan 3b occurred in an overall 90% 
yield over two steps of alkylation and deprotection (Scheme 
4).  
 
Scheme 4. Synthesis of isosorbide-5-furoxans 4b and 
4c and X-ray crystal structure depicting one of the 
two molecules in the asymmetric unit cell of 4c 
(thermal ellipsoids set at 50% probability) 
 
It is known that NO–production can be increased by 
substituting the furoxan ring with electron-withdrawing 
groups, such as nitrobenzene, which effectively increase 
susceptibility to addition of activating thiols (such as 
cysteine).13,14 Thus, in a quest to increase the activity of 
isosorbide-5-furoxan, the preparation of p-nitro derivative 4c 
was carried out from isosorbide-2-acetate 2b and bromide 7b 
(Scheme 4). p-Nitrophenyl-substituted furoxan 4c was 
isolated in 85% yield without the requirement for isolation of 
the intermediate isosorbide-2-acetate-5-furoxan.  
To further increase the level of NO-release, isosorbide 
was functionalized with two furoxan moieties. The 
preparation of isosorbide-2,5-difuroxan 8 was achieved in 
77% isolated yield by facile alkylation of 1 with 7a in the 
presence of Ag2O (Scheme 5). The X-ray crystal structure of 
bis-adduct 8 was obtained, and like the other two crystal 
structures (of 3a and 4c) provided a clear visual 
representation of the 2-exo and 5-endo isosorbide 
attachments (Schemes 3-5). H-bonding in the lattice only 
occurred in 4c, presumably due to the isosorbide hydroxyl 
being deacetylated, (Fig. S10 and Table S5B). 
 
Scheme 5. Synthesis and X-ray crystal structure of 
isosorbide-2,5-difuroxan 8 (thermal ellipsoids set at 
30% probability) 
 
 
NO-release from our isosorbide furoxans was 
quantitatively measured along with that of the commercial 
vasodilator, Is5N. Furoxans have long been known to release 
NO upon reaction with thiols, including cysteine.12 DFT 
calculations supported the addition of a sulfanyl radical onto 
the C=N bond of the furoxan followed by expulsion of NO,27 
although others give alternative thiolate addition 
mechanisms,12,14 which are energetically less favourable.27 
NO-release holds a reasonable correlation with vascular 
tissue relaxation in a series of furoxans.11,12 NO is, however, 
never measured directly due to very rapid oxidation in 
aqueous and biological fluids to nitrite (NO2-) and nitrate 
(NO3-).12,14 The amount of NO-released is commonly 
evaluated through NO2- measurement using the Griess assay, 
in the presence of excess cysteine with the presence of NO3- 
deemed less significant. Using this approach, NO2- 
production from isosorbide-furoxans 3a, 4a-4c and 8 was 
quantitatively monitored by regular sampling (Figure S4), 
which indicated a 3-7.5 fold greater rate of release than Is5N 
(kobs, Table 2). After 12 h a significant slowdown for most 
furoxans was observed, apart from isosorbide-2,5-difuroxan 
8, which exhibited a longer sustained NO-release. This 
retardation in NO release allowed measurement of the extent 
of NO2- production after 24 h (Table 2). A thorough approach 
was used with combined NO2- and NO3- measured. 
 Nowadays this is possible using a commercially available 
colorimetric assay that measures total available NO2- after 
reduction of NO3- to NO2- by NADPH in the presence of the 
enzyme, nitrate reductase.28 Moreover, Table 2 shows NO3- 
levels were significant for some furoxans, especially the most 
reactive compounds highlighting the need for analysis.  
 
Table 2. Extent and rate of NO release 
a Determined by Griess assay after 24 h incubation of 2.0 mM 
solutions with excess L-cysteine at 37 °C. b Samples of 
solutions after 24 h incubated with nitrate reductase prior to 
performing Griess assay. c Rate constant (kobs) for NO2- 
production calculated by linear regression analysis of 0-4 h 
data points for 4c and 0-8 h data points for all other 
compounds in Figure S4. 
 
The p-nitrophenyl-substituted derivative furoxan 4c had 
a significantly higher rate of NO-release, with this compound 
being the most active, with 2-2.5 times greater rate of NO2- 
production compared to isosorbide-2- and 5-furoxans 4a and 
4b. High concentrations of NO have been related to anti-
cancer activity for some furoxans.29 The acetate group of 3a 
appeared to hinder NO-release with a slower rate, as well as a 
smaller total amount of NO produced compared to its 
hydrolyzed derivative 4a. As expected, substituting both 
available hydroxyls on isosorbide with furoxan in compound 
8 almost doubled the extent of NO production, but the rate 
of NO-release was below that of the most reactive mono-
substituted isosorbide furoxan 4c. Isosorbide-2-furoxan 4a 
gave higher levels of NO-release compared to its isomer 4b, 
and pharmacologically they would be expected to behave 
differently as shown by the drug Is5N, which is less potent 
than isosorbide-2-mononitrate (Is2N), as a vasodilator.30 
Differential Scanning Calorimetry (DSC) was used for 
assessment of thermally induced energy release,31 which 
allows deductions regarding safe handling in comparison 
with Is5N, which is classified as an explosive.32 The onset 
temperature for thermal degradation of phenyl furoxans (4a, 
4b and 8) is less accessible at 66-94 °C above that of Is5N 
(Table 3). Similarly, the degradation exotherms peaked 61-
73 °C above that of Is5N. The energy released from such 
exothermic events was lower for the phenyl furoxans by 
1086-1614 J/g. The most active NO-releasing furoxan, p-
nitrophenyl furoxan 4c is safer than Is5N with a significantly 
higher onset and peak temperature by almost 32 °C and 41 °C 
respectively, and with an energy release 1099 J/g lower. 
In summary, inexpensive MeMgCl-mediated acetylation 
has afforded an effective and simple protection-deprotection 
for both hydroxyls of isosorbide. Subsequent 
functionalization with furoxan gave powerful nitric oxide 
donors with vastly higher rates and amounts of NOX 
produced compared to the commercial vasodilator, Is5N. 
Isosorbide-furoxans are safer to handle than Is5N. Future 
studies will focus on the biological evaluation of this new 
class of NO-donors.  
 
Table 3. Exothermic events a  
 a DSC was performed using 1.7-4.6 mg of samples in a high 
pressure crucible, heating at 5 °C/min. b  Temperature at 
which the exothermic event begins. c Temperature of 
maximal heat release. d Calculated by integration. 
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